Chairman, CEO and Co-Founder
Frédéric Cren has served as our Chief Executive Officer since co-founding Inventiva in 2011, and as the chairman of our board of directors since May 2016.
Previously, he served as the General Manager, Research of Abbott Laboratories from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, including Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, and at Laboratoires Fournier SA prior to its acquisition by Solvay in 2005. Positions at Laboratoires Fournier included: Vice-President, Strategic Marketing and Vice-President, U.S. Operations. Furthermore, Mr. Cren served as a member of the Executive Committees of both Solvay Pharmaceuticals and Laboratoires Fournier. Before joining the pharmaceutical industry, Mr. Cren was a consultant with The Boston Consulting Group in their healthcare practice for eight years.
Mr. Cren received a master’s degree in business administration from INSEAD, a master’s degree in international relations from Johns Hopkins University and a bachelor’s degree in economics from Paris IX Dauphine University.
Pierre Broqua, Ph.D.
CSO and Co-Founder
Pierre Broqua has served as our Chief Scientific Officer since co-founding Inventiva in 2011, and as our Deputy Chief Executive Officer and a member of our board of directors since May 2016.
Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005.
He holds a Ph.D. in pharmacology from the University of Paris Descartes and a master’s degree in chemistry and biochemistry from Université Pierre et Marie Curie, Paris.
Chris Buyse has served as a member of our board of directors since February 2017. Chris Buyse is currently the managing partner of Fund+, which is a life sciences investment fund that he co-founded in 2015.
Previously, Mr. Buyse was Chief Financial Officer at ThromboGenics NV, a public biotechnology company, from 2006 to 2014. He was previously Chief Financial Officer of CropDesign N.V, a Belgian biotechnology company.
Before this, he was Finance Director of WorldCom/MCI Belgium-Luxembourg, a telecommunications company, was Chief Financial Officer and interim Chief Executive Officer of Keyware Technologies N.V., an IT company, and held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent director of Celyad SA, a public biotechnology company, as well as iTeos Therapeutics SA, and Bioxodes SA, each of which are biotechnology companies.
Mr. Buyse holds a master’s degree in applied economic sciences from the University of Antwerp and a master’s degree in business administration from the Vlerick School of Management in Ghent.
Jean-Louis Junien has served as a member of our board of directors since 2016.
He has held various senior management positions in the pharmaceutical industry, including as Director of Jouveinal Research Institute and General Manager of Jouveinal Laboratoires, from 1981 to 1993, as Vice President Research and Development at Jouveinal-Warnert Lambert from January 1993 to May 1995, as Director of the Ferring Research Institutes in Southampton (United Kingdom) and La Jolla (United States) from 1995 to 1998, and as Global Chief Scientific Officer for Ferring Holding SA, a pharmaceutical company, from 1998 to 2000. From 2000 to 2007, he was Chief Scientific Officer of Laboratoires Fournier SA. Mr. Junien founded ISLS Consulting in 2007 and is its Chief Executive Officer.
Mr. Junien holds a doctor of pharmacy degree from the University of Paris Descartes and has received degrees in pharmacology and physiology from the Universities of Pharmacy and Biological Science in Paris and in human biology from the University of Medicine in Paris. He received the Galien Prize, an award for pharmaceutical research, in 1992.
Lucy Lu has served as a member of our board of directors since May 2018.
She has been the President and Chief Executive Officer of Avenue Therapeutics, Inc., a public biotechnology company, since its inception in 2015. Previously, she was Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc. from 2012 to 2017.
Before working in the biotechnology industry, Dr. Lu worked in healthcare-related equity research and investment banking, including as Senior Biotechnology Analyst at Citigroup Inc. from 2007 to 2012. She currently serves as a board member of Veru Inc., a public biopharmaceutical company.
Dr. Lu holds a doctor of medicine degree from the New York University School of Medicine and a master’s degree in business administration from the Leonard N. Stern School of Business at New York University. She also received a bachelor’s degree from the University of Tennessee’s College of Arts and Science.
Nanna Lüneborg has served as a member of our board of directors since May 2017.
Since 2012, she has been a Partner at Novo Holdings A/S, a global life science investor. Prior to joining Novo Holdings she was part of the life science investment team at Apposite Capital, a venture capital firm specializing in healthcare, from 2008 to 2012.
Dr. Lüneborg has previously served on the board of directors of ObsEva SA and Orphazyme A/S, which are each biotechnology companies. She currently serves on the boards of ReViral Ltd, NBE Therapeutics, GmBH, Stargazer Pharmaceuticals, Inc. and Epsilon-3 Bio Limited, which are each biotechnology companies.
Dr. Lüneborg holds a bachelor’s degree from University of Oxford, a doctor of philosophy degree in neuroscience from University College London, and a master’s degree in business administration from University of Cambridge.
Chris Newton has served as a member of our board of directors since February 2017.
Dr. Newton founded, and then served as Chief Scientific Officer and a member of the board of directors of, Argenta Discovery Ltd, a company in the contract research organization sector, from 2000 to 2005. He was the Chief Scientific Officer and a member of the board of directors of BioFocus, plc, a contract research organization, from July 2005 to October 2005 and then served as the Senior Vice President of Galapagos NV, a biotechnology company, and Managing Director of BioFocus, after the acquisition of BioFocus by Galapagos NV, until 2013.
Dr. Newton then served as Vice President, Alliances, of Galapagos from 2013 until his retirement in April 2015. Since then Dr. Newton has served as a consultant in the biotechnology and pharmaceutical industries.
Dr. Newton holds a first class master’s degree in natural sciences from the University of Cambridge and a master’s and a doctor of philosophy degree in chemistry from the University of Sheffield.
Annick Schwebig has served as a member of our board of directors since February 2017.
In 2000, she founded Actelion Pharmaceuticals France SAS, a pharmaceuticals company specializing in developing drugs for orphan diseases, and was its Chairman and Chief Executive Officer from 2000 to 2015. Ms. Schwebig has held senior positions in the pharmaceutical industry, including Vice President Medical Affairs France and Vice President Research and Development Europe at Bristol-Myers Squibb from 1983 to 2000.
Ms. Schwebig has been a member of the board of directors of Cellectis SA, a biotechnology company, since 2011. Ms. Schwebig is a graduate of the Paris Faculty of Medicine.